DE602005014828D1 - ME-5, ME-2, and EPP2: menschliche Proteinantigene, die mit Autoantikörpern reagieren, die im Serum von Frauen vorliegen, die an Endometriose leiden - Google Patents

ME-5, ME-2, and EPP2: menschliche Proteinantigene, die mit Autoantikörpern reagieren, die im Serum von Frauen vorliegen, die an Endometriose leiden

Info

Publication number
DE602005014828D1
DE602005014828D1 DE602005014828T DE602005014828T DE602005014828D1 DE 602005014828 D1 DE602005014828 D1 DE 602005014828D1 DE 602005014828 T DE602005014828 T DE 602005014828T DE 602005014828 T DE602005014828 T DE 602005014828T DE 602005014828 D1 DE602005014828 D1 DE 602005014828D1
Authority
DE
Germany
Prior art keywords
endometriosis
epp2
serum
react
human protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005014828T
Other languages
English (en)
Inventor
El Shami A Said
Bruce Campbell
Dennis Sustarsic
Niver Sahakian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Siemens Healthcare Diagnostics Inc
Original Assignee
Siemens Healthcare Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Siemens Healthcare Diagnostics Inc filed Critical Siemens Healthcare Diagnostics Inc
Publication of DE602005014828D1 publication Critical patent/DE602005014828D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/364—Endometriosis, i.e. non-malignant disorder in which functioning endometrial tissue is present outside the uterine cavity
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/811—Drug, bio-affecting and body treating compositions involving sex selection or contraception
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/85—Reproductive organs or embryos
    • Y10S530/852—Sperm
    • Y10S530/853—Ovary; eggs; embryos
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance
DE602005014828T 2004-07-07 2005-06-30 ME-5, ME-2, and EPP2: menschliche Proteinantigene, die mit Autoantikörpern reagieren, die im Serum von Frauen vorliegen, die an Endometriose leiden Active DE602005014828D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/887,540 US20060008876A1 (en) 2004-07-07 2004-07-07 ME-5, ME-2, and EPP2: human protein antigens reactive with autoantibodies present in the serum of women suffering from endometriosis

Publications (1)

Publication Number Publication Date
DE602005014828D1 true DE602005014828D1 (de) 2009-07-23

Family

ID=35124497

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005014828T Active DE602005014828D1 (de) 2004-07-07 2005-06-30 ME-5, ME-2, and EPP2: menschliche Proteinantigene, die mit Autoantikörpern reagieren, die im Serum von Frauen vorliegen, die an Endometriose leiden

Country Status (9)

Country Link
US (7) US20060008876A1 (de)
EP (1) EP1614692B1 (de)
JP (1) JP2006051019A (de)
AT (1) ATE433462T1 (de)
AU (1) AU2005202925A1 (de)
CA (1) CA2509632A1 (de)
DE (1) DE602005014828D1 (de)
ES (1) ES2326324T3 (de)
NZ (1) NZ541063A (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8329399B2 (en) * 2006-10-27 2012-12-11 Siu K W Michael Endometrial biomarkers
US8279789B2 (en) * 2008-06-10 2012-10-02 Qualcomm Incorporated Intelligent setting of hysteresis activation timer to enter hysteresis sooner and save battery
US20110171291A1 (en) * 2010-01-07 2011-07-14 Sanford-Burnham Medical Research Institute Pathologically-activated therapeutics
DE102012002929A1 (de) 2012-02-14 2013-08-14 Jürgen Lewald Minimalinvasives Verfahren für die Diagnose und die Therapieverlaufskontrolle der Endometriose

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US652187A (en) * 1899-11-02 1900-06-19 Sigvald Krohn System of electrical distribution.
US4489166A (en) * 1982-05-27 1984-12-18 Research Corporation Monitoring of human endometrial function by radioimmunoassay of PEP
AU5068090A (en) 1989-03-07 1990-09-13 Adeza Biomedical Corporation Endometriosis diagnosis methods and reagents
ATE141278T1 (de) 1991-03-15 1996-08-15 Hoffmann La Roche Diphosphonsaurederivate als zwischenprodukte zur herstellung von diphosphinliganden
CA2062675A1 (en) 1991-04-09 1992-10-10 Sandra S. Fenton Endometrial antigen, composition, test kit and method for endometrial antibody determination
WO1994028021A1 (en) * 1993-05-28 1994-12-08 Medical University Of South Carolina Endometrial proteins, antigenic compositions and methods for detecting endometriosis
US5877284A (en) * 1993-08-12 1999-03-02 The Trustees Of The University Of Pennsylvania Isolated chemotactic factor from patients with endometriosis
US6531277B2 (en) * 1994-10-25 2003-03-11 The Curators Of The University Of Missouri Endometriosis-specific secretory protein
US5843673A (en) * 1994-10-25 1998-12-01 Curators Of The University Of Missouri Method of screening for endometriosis
US7122322B2 (en) * 1994-10-25 2006-10-17 The Curators Of The University Of Missouri Endometriosis-specific secretory protein
US6376201B2 (en) * 1994-12-28 2002-04-23 Procrea Biosciences Inc. Use of ligands specific to major histocompatibility complex-class I antigens for diagnosing endometriosis
US5618680A (en) * 1994-12-28 1997-04-08 Institut De Medecine De La Reproduction De Montreal Use of ligands specific to major histocompatibility complex-class I antigens for diagnosing endometriosis
WO1997035016A1 (en) 1996-03-18 1997-09-25 Novo Nordisk Biotech Inc Polypeptides having phytase activity and nucleic acids encoding same
WO1997035018A1 (en) 1996-03-21 1997-09-25 New York University Growth factor inducible serine/threonine phosphatase fin13
US6294662B1 (en) * 1996-08-27 2001-09-25 University Of South Florida Nucleic acids encoding an endometrial bleeding associated factor (ebaf)
JP2001516009A (ja) 1997-07-17 2001-09-25 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ ガン関連核酸及びポリペプチド
US6165767A (en) * 1998-03-20 2000-12-26 Incyte Pharmaceuticals, Inc. Protein phosphatase-related molecules
NZ508690A (en) * 1998-06-04 2003-05-30 Reprogen Inc Use of cathepsin S in the diagnosis and treatment of endometriosis
WO1999063116A2 (en) 1998-06-04 1999-12-09 Reprogen, Inc. Use of prothymosin in the diagnosis and treatment of endometriosis
US6525187B1 (en) * 1998-07-31 2003-02-25 Diagnostic Products Corporation Polynucleotide encoding autoantigens associated with endometriosis
WO2000043789A1 (en) 1999-01-25 2000-07-27 Procrea Biosciences Inc. Method and diagnostic kit for diagnosis of endometriosis
US6540980B1 (en) * 1999-04-02 2003-04-01 Center For Molecular Medicine And Immunology Method of detecting endometriosis
WO2000063675A1 (en) 1999-04-16 2000-10-26 Bioincept, Inc. Identification of a serum marker for endometriosis
CA2375424A1 (en) * 1999-06-03 2000-12-14 Curagen Corporation Novel polynucleotides and polypeptides encoded thereby
EP1238104A2 (de) 1999-11-03 2002-09-11 Metris Therapeutics Limited Mit endometriose in verbindung stehende agenzien
GB0004232D0 (en) 2000-02-24 2000-04-12 Zeneca Ltd Diagnostic method
CA2399259A1 (en) * 2000-02-25 2001-08-30 Metriogene Biosciences Inc. Endometriosis-related markers and uses thereof
US20010044158A1 (en) * 2000-04-19 2001-11-22 Yeaman Grant R. Diagnostic assay for endometriosis
US6645725B2 (en) * 2000-04-19 2003-11-11 Research Corporation Technologies, Inc. Diagnostic assay for endometriosis
DE10048633A1 (de) 2000-09-25 2002-04-18 Schering Ag Methode zur in vitro Diagnostik von Endometriose
US6780594B2 (en) * 2000-09-25 2004-08-24 Schering Aktiengesellschaft Method for in vitro diagnosis of endometriosis
AU2002255478A1 (en) 2001-01-10 2002-09-12 Pe Corporation (Ny) Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
US7049069B2 (en) * 2001-07-17 2006-05-23 University Of Florida Detecting and treating reproductive tract disorders
US20070224201A1 (en) * 2002-10-02 2007-09-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2004087874A2 (en) 2003-03-28 2004-10-14 Nuvelo, Inc. Novel nucleic acids and polypeptides
WO2005019258A2 (en) * 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US6843673B1 (en) * 2004-04-30 2005-01-18 Speed Tech Corp. Coaxial connector structure

Also Published As

Publication number Publication date
ES2326324T3 (es) 2009-10-07
US7981626B2 (en) 2011-07-19
US20110201129A1 (en) 2011-08-18
AU2005202925A1 (en) 2006-02-02
US20070141600A1 (en) 2007-06-21
US20100062453A1 (en) 2010-03-11
ATE433462T1 (de) 2009-06-15
CA2509632A1 (en) 2006-01-07
US20060008876A1 (en) 2006-01-12
JP2006051019A (ja) 2006-02-23
US7879562B2 (en) 2011-02-01
US20080153106A1 (en) 2008-06-26
US20070178528A1 (en) 2007-08-02
US20100330696A1 (en) 2010-12-30
EP1614692A3 (de) 2006-04-05
EP1614692A2 (de) 2006-01-11
US8030007B2 (en) 2011-10-04
NZ541063A (en) 2008-07-31
EP1614692B1 (de) 2009-06-10

Similar Documents

Publication Publication Date Title
Vitale et al. HLA class I antigen down-regulation in primary ovary carcinoma lesions: association with disease stage
WO2003024993A3 (en) Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using elisa assays
US11965895B2 (en) Methods and devices female health monitoring
WO2005108989A3 (en) Assay for antibodies
BRPI0414030A (pt) método para detectar desordens neoplásicas em uma amostra corporal solubilizada
WO2003000853A3 (en) Protein aggregation assays and uses thereof
WO2004058171A3 (en) Antibodies against gpr64 and uses thereof
EP2287618A3 (de) Verfahren zur Diagnose neurodegenerativer Erkrankungen
DK1565489T3 (da) Internaliserende antistoffer specifikke for RAAG10-celleoverflademålet
WO2005080985A3 (en) Methods and compositions for detecting and treating autoimmune diseases
SG166788A1 (en) Use of b cell expansion agents in generating antibodies
WO2002067760A3 (en) Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays
WO2004111081A3 (en) Antigenic peptides of sars coronavirus and uses thereof
ATE433462T1 (de) Me-5, me-2, and epp2: menschliche proteinantigene,die mit autoantikörpern reagieren, die im serum von frauen vorliegen, die an endometriose leiden
WO2009126969A3 (en) Biomarkers for endometrial disease
WO2007098198A3 (en) Modulation of bone formation
Zargaran et al. A comparative study of cathepsin D expression in peripheral and central giant cell granuloma of the jaws by immunohistochemistry technique
WO2004022006A3 (en) Methods of diagnosing cervical cancer
TR200102877T2 (tr) İmmünoglobulinin kendi yüksek afinite reseptörüne bağlanmasını inhibe eden antikorlara karşı anti-idiotipik antikorlar.
WO2022020234A3 (en) Immunoassay for sars-cov-2 neutralizing antibodies and materials therefor
WO2004094476A3 (en) Compositions and methods relating to stop-1
WO2005029089A3 (en) Method of diagnosing ovarian endometriosis using tfpi-2 protein
ATE412180T1 (de) Verfahren und mittel zum nachweis von durch gluten induzierten krankheiten
EP2527359A3 (de) Diagnostischer Assay
WO2003024304A3 (en) Detection and treatment of cancers of the liver

Legal Events

Date Code Title Description
8364 No opposition during term of opposition